Tryptamine Therapeutics Limited (ASX:TYP)

Tryptamine Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Net Income	-5.33	-7.37	-5.85	-8.35	-8.94
Depreciation & Amortization	0.05	0.01	-	-	-
Asset Writedown & Restructuring Costs	0.14	-	-	-	1.04
Stock-Based Compensation	0.04	1.8	0.4	0.64	2.81
Other Operating Activities	0.03	1.24	0.22	-	-
Change in Accounts Receivable	-	-	-	0.02	-0.02
Change in Accounts Payable	-0.97	-0.76	0.86	1.12	-0
Change in Other Net Operating Assets	-1.73	-2.12	0.34	0.09	-0.37
Operating Cash Flow	-7.77	-7.2	-4.03	-6.47	-5.48
Capital Expenditures	-0.13	-	-	-	-
Cash Acquisitions	-	2.02	-	-	-
Sale (Purchase) of Intangibles	-0	-	-0.01	-0.15	-0.03
Investing Cash Flow	-0.13	2.02	-0.01	-0.15	-0.03
Short-Term Debt Repaid	-	-	-	-	-0
Total Debt Repaid	-	-	-	-	-0
Net Debt Issued (Repaid)	-	-	-	-	-0
Issuance of Common Stock	6	11.87	2.39	4.65	9.18
Other Financing Activities	-0.4	-0.74	-	-0.04	-0.78
Financing Cash Flow	5.6	11.12	2.39	4.61	8.4
Foreign Exchange Rate Adjustments	0.01	-0.03	0	-	-
Net Cash Flow	-2.3	5.91	-1.65	-2.02	2.89
Free Cash Flow	-7.9	-7.2	-4.03	-6.47	-5.48
Free Cash Flow Margin	-499.43%	-542.48%	-	-	-
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.08	-0.11
Cash Interest Paid	0.01	0	-	-	-
Levered Free Cash Flow	-5.77	-	-2.07	-3.42	-2.61
Unlevered Free Cash Flow	-5.76	-	-1.58	-3.42	-2.61
Change in Working Capital	-2.7	-2.88	1.2	1.23	-0.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.